focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLPE.L Regulatory News (SLPE)

  • There is currently no data for SLPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Quarterly Trading Statement

20 Mar 2013 07:00

RNS Number : 3786A
Standard Life Euro Pri Eqty Tst PLC
20 March 2013
 

 

 

 

Standard Life European Private Equity Trust PLC

 

1. Investment update for the quarter from 1 October to 31 December 2012

 

·; NAV increased 1.3% to 230.5p for the quarter ended 31 December 2012

·; Net realised gains/income and unrealised gains on a constant exchange rate basis rose 0.3%, while there was an unrealised foreign exchange gain of 1.4%

·; 100% by value of the portfolio was valued by the respective underlying managers at 31 December 2012

·; Outstanding commitments were £154.7 million at 31 December 2012

·; Net cash balance was £3.1 million at 31 December 2012

 

For the quarter ended 31 December 2012 the Company's net asset value per ordinary share ("NAV") increased by 1.3% to 230.5p (diluted NAV - 227.7p), from 227.6p at 30 September 2012 (diluted NAV - 224.9p). At 31 December 2012 the Company's net assets were £374.0 million (30 September 2012 - £369.7 million).

 

The quarter ended 31 December 2012 saw an increase in new investment and realisation activity in the European private equity market, notably for transactions with an enterprise value over €1 billion. The value of all new private equity transactions in the European private equity market announced during the quarter was €24.6 billion (quarter ended 30 September 2012 - €13.5 billion), of which €22.8 billion comprised buy-out transactions (quarter ended 30 September 2012 - €12.3 billion).

 

Distributions received by the Company during the quarter ended 31 December 2012 were £17.3 million (quarter ended 30 September 2012 - £32.0 million) and the Company funded £15.4 million of draw downs (quarter ended 30 September 2012 - £15.9 million). The distributions received by the Company generated net realised gains and income of £9.3 million. In addition, the Company incurred a book loss of £6.5 million on the commencement of the liquidation process for two older funds, Alchemy Investment Plan and the Candover 1997 Fund, where all of the underlying investments have been realised. Importantly, the book loss had previously been provided for in the Company's valuation of the respective fund interests.

 

The closing value of the Company's portfolio of 39 private equity fund interests was £370.4 million at 31 December 2012 (30 September 2012 - 37 fund interests and £365.9 million). Total net unrealised gains on the portfolio for the quarter were £3.6 million, of which £1.6 million were net unrealised losses on a constant exchange rate basis and £5.2 million were net unrealised foreign exchange gains. During the quarter ended 31 December 2012 sterling depreciated by 1.8% against the euro and appreciated by 0.7% against the US dollar.

 

In line with the Company's investment strategy, a new commitment of €20.0 million was made to Advent Global Private Equity VII in November 2012 and one of €30.0 million was made to IK VII in December 2012. The Company has invested in prior funds of each of the respective managers. At 31 December 2012 the Company had aggregate outstanding commitments of £154.7 million (30 September 2012 - £129.0 million).

 

At 31 December 2012 the Company had a net cash balance of £3.1 million (30 September 2012 - net cash balance of £3.5 million).

 

On 31 December 2012 the Company announced that it had entered into a new £80 million revolving credit facility, led by The Royal Bank of Scotland plc, replacing the Company's existing debt facility. The new debt facility expires on 31 December 2016.

 

 

2. Events and transactions since 1 January 2013

 

During January 2013 the Company completed the purchase of an original commitment of €7.0 million to Charterhouse Capital Partners IX, a fund the Company was not able to commit to when it was raised in 2009. The fund interest was acquired at a 5% discount to the 30 June 2012 valuation of the fund, adjusted for subsequent cashflows. The purchase price for the interest was £2.8 million and the Company assumed £2.8 million of outstanding commitments.

 

As part of a portfolio rebalancing exercise, and given the significant exposure to the fund and its underlying investments, the Company also completed the sale of 50% of its original commitment to Charterhouse VIII in February 2013. The fund interest was sold at an 11% discount to the 30 September 2012 valuation of the fund, adjusted for subsequent cashflows. The sale price for the interest was £16.3 million and the Company was released from £3.5 million of outstanding commitments. Adjusting the NAV at 31 December 2012 disclosed in section 1 above for the disposal of the interest in Charterhouse VIII would have reduced the NAV by 1.2p, or 0.5%.

 

Excluding the above secondary transactions, during the period from 1 January to 18 March 2013 the Company received £4.5 million of distributions and funded £2.3 million of draw downs. At 18 March 2013 the Company had a net cash balance of £16.0 million.

 

Finally, the Company made a new commitment of $35 million to TowerBrook Investors IV in February 2013. Again the Company has invested in prior funds of the manager. Accordingly, at 18 March 2013 the Company had aggregate outstanding commitments of £182.9 million.

 

It is anticipated that the Company will release its interim announcement for the six months ending 31 March 2013 on or around 30 May 2013.

 

For further information please contact:-

 

Peter McKellar of SL Capital Partners LLP (0131 245 0055)

 

Note:-

Standard Life European Private Equity Trust PLC is an investment company managed by SL Capital Partners LLP, the ordinary shares of which are admitted to listing by the UK Listing Authority and to trading on the Stock Exchange and which seeks to conduct its affairs so as to qualify as an investment trust under sections 1148 - 1165 of the Corporation Taxes Act 2010. The Board of Standard Life European Private Equity Trust PLC is independent of Standard Life plc.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEKLFFXXFEBBD
Date   Source Headline
4th Apr 202212:06 pmRNSChange of Name
22nd Mar 20222:14 pmRNSResult of AGM
21st Mar 202211:26 amRNSDirector Declaration
14th Mar 20225:30 pmRNSFTSE Russell Indices
14th Mar 20227:00 amRNSEstimated NAV at 28 February 2022
9th Mar 20222:07 pmRNSFirst Interim Dividend
24th Feb 20227:00 amRNSEdison review on Standard Life Private Equity Trst
14th Feb 20227:00 amRNSEstimated NAV at 31 January 2022
4th Feb 20223:24 pmRNSAnnual Report
1st Feb 202212:45 pmRNSDirector/PDMR Shareholding
27th Jan 20227:05 amRNSEstimated NAV at 31 December 2021
27th Jan 20227:00 amRNSAnnual Financial Report
6th Jan 20229:04 amRNSQuarterly disclosure
15th Dec 20217:00 amRNSEstimated NAV as at 30 November 2021
14th Dec 20213:48 pmRNSFourth Interim Dividend
6th Dec 20217:00 amRNSEdison review on Standard Life Private Equity Trst
12th Nov 20217:00 amRNSEstimated NAV at 31 October 2021
2nd Nov 20214:25 pmRNSDirector/PDMR Shareholding
14th Oct 20217:00 amRNSEstimated NAV at 30 September 2021
4th Oct 20214:15 pmRNSQuarterly disclosure
29th Sep 20217:02 amRNSEstimated NAV at 31 August 2021
29th Sep 20217:00 amRNSQuarterly Investment Update at 30 June 2021
17th Sep 20211:10 pmRNSUpdate research from QuotedData
7th Sep 20217:00 amRNSThird Interim Dividend
1st Sep 20217:00 amRNSDirectorate Change
16th Aug 202110:19 amRNSDirector/PDMR Shareholding
13th Aug 20217:00 amRNSEstimated NAV at 31 July 2021
10th Aug 20214:41 pmRNSSecond Price Monitoring Extn
10th Aug 20214:35 pmRNSPrice Monitoring Extension
5th Aug 20213:32 pmRNSDirector/PDMR Shareholding
19th Jul 202111:58 amRNSEdison issues review on Standard Life Private
14th Jul 20219:05 amRNSDirector Declaration
14th Jul 20217:00 amRNSEstimated NAV at 30 June 2021
9th Jul 20213:29 pmRNSDoc re. Half yearly report
2nd Jul 20214:35 pmRNSQuarterly disclosure
29th Jun 20217:05 amRNSEstimated NAV at 31 May 2021
29th Jun 20217:00 amRNSHalf-year Report
14th Jun 20212:48 pmRNSSecond Interim Dividend
17th May 20217:00 amRNSEstimated NAV at 30 April 2021
12th May 20214:06 pmRNSDirector/PDMR Shareholding
27th Apr 202112:21 pmRNSDirector/PDMR Shareholding
22nd Apr 20217:05 amRNSEstimated NAV at 31 March 2021
22nd Apr 20217:00 amRNSQuarterly Investment Update at 31 December 2020
9th Apr 202111:58 amRNSHolding(s) in Company
6th Apr 20214:11 pmRNSQuarterly disclosure
23rd Mar 20211:50 pmRNSResult of AGM
12th Mar 20217:00 amRNSEstimated NAV as at 28 February 2021
8th Mar 20217:00 amRNSFirst Interim Dividend
25th Feb 20217:00 amRNSEdison review on Standard Life Private Eqty Trust
12th Feb 202110:22 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.